본문 바로가기
  • Home

The Effects of Baicalein on Osteoclast Differentiation from Bone Marrow Derived Macrophage

Yeon Jin Yi 1 Cheon Yoon-Hee 2 김주영 1 곽성철 1 윤강휴 1 백종민 1 이명수 1 오재민 1 박종태 1

1원광대학교
2원광대학교 영상의학기반 폐 및 골 질환연구센터

Accredited

ABSTRACT

As prediction of rapidly aging society, bone health is considered increasingly important and receivedmore attention than ever. Bone health is regulated by balancing between bone resorptive osteoclasts and boneformative osteoblasts. Disruption of balance between bone-resorbing osteoclasts and bone-forming osteoblastsresults in bone disease. Natural products have recently received much attention as an alternative tool for thedevelopment of novel therapeutic strategy. Baicalein is reported it has anti-cancer, anti-inflammatory andantioxidant effects. Baicalein also has been known that it has both promotive effect on MC3T3-E1 cell line andinhibitory effect on RAW 264.7 cell line. However, the inhibitory mechanism of baicalein using bone marrowderived macrophages (BMMs) on osteoclast differentiation remains not clear. In this study, the suppressivemechanism by baicalein on osteoblast differentiation was evaluated. Bicalein inhibited receptor activator ofnuclear factor-κB ligand (RANKL)-induced osteoclast differentiation in BMMs in a dose dependent mannerwithout any toxicity. Baicalein suppressed phosphorylation of protein kinaseB (Akt), c-Jun N-terminal kinases(JNK) and phosphoinositide-specific phospholipaseCγ2 (PLCγ2). Furthermore, Baicalein suppressed theinduction of RANKL-induced c-Fos and Nuclear factor of activated T cell c1 (NFATc1), essential genes onosteoclastogenesis. In BMMs, Bicalein inhibited the mRNA expression of tartrate-resistant acid phosphatase(TRAP), osteoclast-associated receptor (OSCAR), cathepsinK, dendritic cell-specific transmembrane protein (DCSTAMP). Moreover, baicalein promoted differentiation of osteoblast on bone marrow stromal cells (BMSCs). Taken together, these results suggest that baicalein has a potential for treating bone lytic diseases, such asosteoporosis, periodontitis, and rheumatoid arthritis.

Citation status

* References for papers published after 2023 are currently being built.